Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BiOpticROCO:6850 +2.80%90 EV-to-EBITDA is 27.03 as of Sep. 10, 2026, which is 29% above its 10-year median of 20.98. GuruFocus rates ROCO:6850 with a GF Score™ of 90/100 and a GF Value™ of NT$43.78 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 401 Biotechnology companies, BiOptic ranks worse than 67.83% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, BiOptic's enterprise value is NT$996.1 Mil.
BiOptic's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was NT$36.9 Mil. Therefore, BiOptic's EV-to-EBITDA for today is 27.03.
The historical rank and industry rank for BiOptic's EV-to-EBITDA or its related term are showing as below:
ROCO:6850'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 11.62 Med: 20.98 Max: 57
Current: 27.03
During the past 8 years, the highest EV-to-EBITDA of BiOptic was 57.00. The lowest was 11.62. And the median was 20.98.
ROCO:6850's EV-to-EBITDA is ranked worse than 67.83% of 401
companies
in the Biotechnology industry
Industry Median: 13.35
vs ROCO:6850: 27.03
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2026-09-10), BiOptic's stock price is NT$33.30.
BiOptic's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was NT$0.260. Therefore, BiOptic's PE Ratio (TTM) for today is 128.08.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
BiOptic's share price for today is NT$33.30.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. BiOptic's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was NT$0.260.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for BiOptic's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6850 vs VRTX, REGN, MRNA: EV-to-EBITDA Comparison
For the Biotechnology subindustry, BiOptic's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BiOptic EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BiOptic's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where BiOptic's EV-to-EBITDA falls into.
BiOptic's current Enterprise Value is NT$996.1 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. BiOptic's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was NT$36.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BiOptic (ROCO:6850) has a EV-to-EBITDA of 27.03 as of Sep. 10, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on BiOptic. This is 29% above median its historical median of 20.98. Over the past decade, BiOptic's EV-to-EBITDA has ranged from 11.62 to 57.00. According to the industry distribution chart, BiOptic ranks #272 out of 401 companies in the Biotechnology industry, placing it in the top 67.8%.
Is BiOptic's EV-to-EBITDA too high?
BiOptic's current EV-to-EBITDA of 27.03 is 29% above median its 10-year median of 20.98. Over the past 10 years, this metric has ranged from a low of 11.62 to a high of 57.00. The Biotechnology industry median EV-to-EBITDA is 13.35. BiOptic's value of 27.03 is 102.5% above this industry median. Based on the distribution chart, BiOptic ranks #272 out of 401 companies in the Biotechnology industry, which is below the industry midpoint. Overall, BiOptic has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BiOptic's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BiOptic ranks #272 out of 401 companies for EV-to-EBITDA. This places BiOptic in the lower half of its industry. The industry median EV-to-EBITDA is 13.35. BiOptic's value of 27.03 is 102.5% above this benchmark. Historically, BiOptic's own EV-to-EBITDA has ranged from 11.62 to 57.00 over the past decade. While the company's 10-year median is 20.98 vs. the industry median of 13.35, BiOptic has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.35, based on 401 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BiOptic's current EV-to-EBITDA of 27.03 is 102.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on BiOptic. For the Biotechnology industry, the median EV-to-EBITDA is 13.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BiOptic's current EV-to-EBITDA is 27.03, which is 29% above median its own 10-year median of 20.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BiOptic stock overvalued right now?
Based on GuruFocus' analysis, BiOptic (ROCO:6850) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$43.78, compared to a current price of NT$33.30 — trading 23.9% below its estimated fair value. The current EV-to-EBITDA is 27.03, which is 29% above median its 10-year median of 20.98 and 102.5% above the Biotechnology industry median of 13.35. BiOptic's overall GF Score™ is 90/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For BiOptic (ROCO:6850), the current EV-to-EBITDA is 27.03 as of Sep. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BiOptic (ROCO:6850) Overvalued in 2026?
Based on GuruFocus' analysis, BiOptic stock appears to be undervalued.
The current stock price of NT$33.30 is trading 23.9% below its estimated GF Value™ of NT$43.78.
GuruFocus considers BiOptic to be Modestly Undervalued.
Key valuation signals for ROCO:6850:
EV-to-EBITDA: 27.03 (29% above median its 10-year median of 20.98)
GF Value™: NT$43.78 vs. price of NT$33.30 (23.9% below fair value)
Industry Position: 102.5% above the Biotechnology median (#272 of 401)
No single metric tells the full story. See the ROCO:6850 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BiOptic Inc is a biotechnology instrumentation company that develops scientific products for research and clinical applications. It serves professionals and laboratories dedicated to life science research, clinical diagnostics, pharmaceutical and food industries, animal husbandry, and agriculture, performing diagnostic molecular genetic analyses.
90GF Score
Get the complete analysis for ROCO:6850
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6850 has been successfully added to your 
